The SARS epidemic is caused by a novel coronavirus (SARS-CoV) that jumped to humans from a wild
animal host. Identifying the natural host of SARS-CoV and other susceptible animals is crucial to control
SARS in humans. SARS-CoV infects the respiratory and intestinal tract but there is little specific information
on target cells for viral replication or damage. The objectives of this proposal are to discover the role of the
expression of the receptor for SARS-CoV and its interaction with the viral S glycoprotein in determining the
host range, tissue tropism, and mechanisms of lung disease in SARS. Our hypothesis is that infection of
macrophages plays a central role in the pathogenesis of SARS. The specific aims are: 1) Determine the
SARS-CoV host range and tissue tropism by studying binding of virus and viral S glycoprotein to isolated
cell membranes of a wide variety of animal species. We will use solid phase binding assays to study host
range and tissue tropism and a virus overlay protein binding assay to determine the molecular mass of the
receptor in positive species; 2) Determine whether SARS-CoV in vitro infection of human macrophage and
dendritic cells leads to their activation, apoptosis, and dysregulated cytokine production. This aim will
require titration of virus, detection of virus infected cells by immunological techniques, and analysis of
cytokine/chemokine production by RNA and protein arrays, and 3) Establish transgenic mice for the SARS-
CoV receptor as models for SARS to study target tissues for viral infection, replication, and tissue damage.
We will analyze lung cell phenotypes and apoptosis by flow cytometry, and evaluate of tissue damage by
histopathology and confocal microscopy. This information and the availability of a mouse model to evaluate
therapeutic interventions will lead to improved diagnosis, treatment and control of SARS. Our research will
identify the actual animal host for SARS-CoV in Asia and potential animal hosts for SARS-CoV in the
United States. Finally, the data will provide information on the mechanism of species jumping.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
041096314
UEI
MW8JHK6ZYEX8
Project Start Date
Project End Date
Budget Start Date
01-June-2007
Budget End Date
31-May-2008
Project Funding Information for 2007
Total Funding
$480,702
Direct Costs
$368,602
Indirect Costs
$112,100
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Allergy and Infectious Diseases
$480,702
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI059576-04 0001
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI059576-04 0001
Patents
No Patents information available for 5P01AI059576-04 0001
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI059576-04 0001
Clinical Studies
No Clinical Studies information available for 5P01AI059576-04 0001
News and More
Related News Releases
No news release information available for 5P01AI059576-04 0001
History
No Historical information available for 5P01AI059576-04 0001
Similar Projects
No Similar Projects information available for 5P01AI059576-04 0001